Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Ahlen – page 58

864 clinical trials in Ahlen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Ahlen at a glance
864
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

864 trials in Ahlen

Open in trial search

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Metastatic Prostate Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Janssen Cilag International

Study on the Effects of Verekitug (UPB-101) for Patients with Chronic Rhinosinusitis with Nasal Polyps Using Nasal Corticosteroids

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Human IgG1 kappa monoclonal antibody against CRLF2
  • Sponsor:Upstream Bio Inc.

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Prostate cancer

Not recruiting

Study of Pembrolizumab, Vibostolimab, and Belzutifan for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Merck Sharp & Dohme LLC

Ovarian cancer stage IV+1

Not recruiting

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Tesaro Inc.

Phenylketonuria

Not recruiting

Study Comparing Sepiapterin and Sapropterin for Treating Phenylketonuria in Patients Aged 2 Years and Older

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sepiapterin
  • Sponsor:PTC Therapeutics Inc.

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2220
  • Sponsor:Alexion Pharmaceuticals Inc.

Study of Emrusolmin for Treating Adults with Multiple System Atrophy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Emrusolmin
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Colon cancer stage II+1

Not recruiting

Study on Adjuvant Therapy with Capecitabine for Stage II Colon and Rectal Cancer Patients with Positive ctDNA After Tumor Removal

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Technische Universitat Dresden

Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Incyte Corp.

Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on Maribavir for Treating Cytomegalovirus in Children and Adolescents Post-Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Maribavir
  • Sponsor:Takeda Development Center Americas Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Ahlen

What the registry says about research in the country

01 Neoplasms (Cancer) Research

In Ahlen, researchers are conducting two recruiting neoadjuvant studies that target HER2+ early breast cancer and triple-negative early breast cancer. The trials compare novel antibody‑drug conjugates with standard chemotherapy regimens, aiming to improve safety profiles and increase pathological complete response rates.

  • Safety profiling of a trastuzumab‑deruxtecan based regimen
  • Efficacy comparison using 3‑year distant disease‑free survival
  • Assessment of sacituzumab govitecan with or without pembrolizumab
  • Evaluation of pathological complete response as a co‑primary endpoint

The single study center in Ahlen enables close coordination between the investigator team and participating patients, fostering rapid enrollment and data collection for these cutting‑edge breast cancer studies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.